
NKGN
Healthcare · Biotechnology · $7.8M market cap
$0.01100.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jan 20, 2026 | Time not confirmed | — | -0.04 | — |
| Oct 8, 2025 | Time not confirmed | — | -0.66 | — |
| Mar 4, 2025 | Time not confirmed | — | 0.15 | — |
| Sep 12, 2024 | After the close | — | -0.67 | — |
| May 20, 2024 | After the close | — | -0.25 | — |
| Mar 31, 2023 | Time not confirmed | — | -0.14 | — |
| Nov 14, 2022 | Time not confirmed | — | 0.04 | — |
| Aug 15, 2022 | Time not confirmed | — | 0.22 | — |
| May 16, 2022 | Time not confirmed | — | 0.09 | — |
| Mar 31, 2022 | Time not confirmed | — | -0.07 | — |
| Nov 15, 2021 | Time not confirmed | — | 0.22 | — |
| Aug 16, 2021 | Time not confirmed | — | -0.20 | — |
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease; and SNK02, which…